Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a double-blind randomized trial of NSC001 in mild to moderate Alzheimer's disease
2024-518563-35-00Phase 2Authorised
- Sponsor
- NSC Therapeutics
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing NSC001 arm with Placebo arm (2 arms). Primary endpoints: Frequency and severity of adverse events and serious adverse events, Changes in clinical and neurological findings and 3 more. Planned start Apr 2025; status: authorised.
02
Drugs
NGX267
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-518563-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518563-35-00.